Running Oak Capital LLC Sells 6,781 Shares of STERIS plc $STE

Key Points

• Running Oak Capital LLC cut its stake in STERIS by 10.1%, selling 6,781 shares and now holding 60,038 shares worth about $15.22 million, making STERIS roughly 1.9% of the fund's portfolio and its 19th largest holding.
• Director Cynthia L. Feldmann sold 3,098 shares at an average price of $237.21 for $734,876, an 81.46% reduction in her position, leaving her with 705 shares.
• Analysts rate STERIS a consensus “Moderate Buy” (six Buys, one Hold) with a $275.20 target; the company met Q results (EPS $2.53), reported revenue up 9.2% YoY, set FY2026 guidance of $10.15–$10.30 EPS, and pays a $0.63 quarterly dividend (1.1% yield).

Running Oak Capital LLC decreased its position in STERIS plc (NYSE:STE - Free Report) by 10.1% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 60,038 shares of the medical equipment provider's stock after selling 6,781 shares during the period. STERIS comprises approximately 1.9% of Running Oak Capital LLC's portfolio, making the stock its 19th biggest holding. Running Oak Capital LLC owned about 0.06% of STERIS worth $15,221,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Steigerwald Gordon & Koch Inc. bought a new position in shares of STERIS in the third quarter worth approximately $25,000. Board of the Pension Protection Fund bought a new position in shares of STERIS in the fourth quarter worth approximately $25,000. Harbor Investment Advisory LLC grew its holdings in shares of STERIS by 115.4% in the fourth quarter. Harbor Investment Advisory LLC now owns 112 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 60 shares during the last quarter. Geneos Wealth Management Inc. grew its holdings in shares of STERIS by 416.0% in the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider's stock worth $29,000 after purchasing an additional 104 shares during the last quarter. Finally, Cloud Capital Management LLC bought a new position in shares of STERIS in the third quarter worth approximately $29,000. Institutional investors own 94.69% of the company's stock.

Insider Activity at STERIS

In other news, Director Cynthia L. Feldmann sold 3,098 shares of the business's stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $237.21, for a total transaction of $734,876.58. Following the sale, the director owned 705 shares in the company, valued at approximately $167,233.05. The trade was a 81.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 1.07% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on STE shares. Wall Street Zen cut shares of STERIS from a "strong-buy" rating to a "buy" rating in a report on Saturday, March 28th. Weiss Ratings reiterated a "buy (b)" rating on shares of STERIS in a report on Friday, January 9th. Six research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, STERIS presently has an average rating of "Moderate Buy" and a consensus target price of $275.20.

STERIS Stock Performance

NYSE:STE opened at $222.43 on Monday. The stock has a market cap of $21.81 billion, a P/E ratio of 31.02 and a beta of 1.07. The firm's fifty day simple moving average is $234.47 and its 200 day simple moving average is $246.79. STERIS plc has a twelve month low of $209.98 and a twelve month high of $269.44. The company has a quick ratio of 1.75, a current ratio of 2.48 and a debt-to-equity ratio of 0.26.

STERIS (NYSE:STE - Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share for the quarter, meeting the consensus estimate of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. The company's revenue for the quarter was up 9.2% on a year-over-year basis. During the same period in the previous year, the company earned $2.32 EPS. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. As a group, research analysts predict that STERIS plc will post 9.08 EPS for the current year.

STERIS Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 19th. Stockholders of record on Tuesday, February 17th were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date was Tuesday, February 17th. STERIS's payout ratio is 35.15%.

STERIS Company Profile

STERIS Corporation NYSE: STE is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.